<DOC>
	<DOC>NCT01257737</DOC>
	<brief_summary>The present protocol is a treatment protocol to allow continued use of HPN-100 for the treatment of UCD subjects who complete 12 months of treatment in Study HPN-100-005, (NCT00947544), HPN-100-007, (NCT00947297), or HPN-100-012, (NCT01347073). Under this protocol, long-term safety will continue to be assessed.</brief_summary>
	<brief_title>To Evaluate the Safety of Long-term Use of HPN-100 in the Management of Urea Cycle Disorders (UCDs)</brief_title>
	<detailed_description>The present protocol will allow subjects continued use of HPN-100 following their treatment and study completion in Study HPN-100-005, HPN-100-007, or HPN-100-012. Subjects will be able to continue in this study until approval and commercial availability of HPN-100 in each country participating in this study. Subjects will be required to return to the clinic every 6 months in which physical exam, safety labs, dietary assessment and neuropsychological testing will occur. Subjects will be dispensed sufficient HPN-100 to last until the next clinic visit.</detailed_description>
	<mesh_term>Disease</mesh_term>
	<mesh_term>Urea Cycle Disorders, Inborn</mesh_term>
	<mesh_term>Glycerol</mesh_term>
	<mesh_term>4-phenylbutyric acid</mesh_term>
	<criteria>Male and female subjects who completed HPN100005,(NCT00947544), HPN100007,(NCT00947297), or HPN100012,(NCT01347073). Signed informed consent by subject and/or subject's legally authorized representative. Negative pregnancy test for all females of childbearing potential. Any clinical or laboratory abnormality or medical condition that, at the discretion of the investigator, may put the subject at increased risk when participating. Known hypersensitivity to PAA,(phenylacetate) or PBA,(phenylbutyrate). Liver transplant, including hepatocellular transplant. Pregnant, breastfeeding or lactating females.</criteria>
	<gender>All</gender>
	<minimum_age>1 Year</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Urea Cycle Disorders</keyword>
	<keyword>GT4P</keyword>
	<keyword>HPN-100</keyword>
	<keyword>Sodium Phenylbutyrate</keyword>
	<keyword>Glyceryl tri-(4-phenylbutyrate)</keyword>
	<keyword>Phenylbutyrate</keyword>
	<keyword>Hyperion</keyword>
	<keyword>Buphenyl</keyword>
	<keyword>hyperammonemia</keyword>
</DOC>